Study of the use of autologous platelet concentrate during pars-plana-vitrectomy for epiretinal gliosis and impending macular hole

Study of the use of autologous platelet concentrate during pars-plana-vitrectomy for epiretinal gliosis and impending macular hole - ATHENA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027852

Enrollment

Registered

2022-01-21

Start date

2019-08-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA 10064697

Interventions

Group 1: Standard therapy with pars plana vitrectomy (23 gauge) and membrane peeling Group 2: Standard therapy with pars-plana-vitrectomy (23 gauge) and membrane peeling and additional intraoperative

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Age = 18 years • Patients with epiretinal gliosis and BCVA = 35 (according to ETDRS). • Written informed consent to participate in the study • Presence of an artificial intraocular lens • Ability to donate autologous platelets

Exclusion criteria

Exclusion criteria: • Patients with own lens • Treatment with intravitreal injections in the previous 3 months in the study eye • Pathological changes of the anterior segment of the eye affecting BCVA (corneal opacities or similar) • Acute inflammation in the study eye • advanced glaucoma with optic atrophy and central visual field defects in the study eye • wet form of age-related macular degeneration as well as advanced form of dry age-related macular degeneration (geographic atrophy) • presence of pregnancy

Design outcomes

Primary

Measure	Time frame
To investigate whether the intraoperative use of autologous platelet concentrate in patients with epiretinal gliosis and impending macular hole leads to better visual recovery than in patients without intraoperative platelet use.	—

Secondary

Measure	Time frame
• Comparison of retinal recovery on OCT between patients with and without intraoperative use from autologous platelet concentrate. • Comparison of visual recovery in patients with primary and secondary epiretinal gliosis. • Comparison of visual recovery in patients with diabetes mellitus and without. • Safety profile of intraoperative use of autologous platelet concentrate.	—

Countries

Germany

Contacts

Public ContactOlga Furashova

Augenklinik der Klinikum Chemnitz gGmbH

augenklinik@skc.de+49 371 33333230

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026